MX2020007183A - Inhibidores de ret9 y vegfr2. - Google Patents
Inhibidores de ret9 y vegfr2.Info
- Publication number
- MX2020007183A MX2020007183A MX2020007183A MX2020007183A MX2020007183A MX 2020007183 A MX2020007183 A MX 2020007183A MX 2020007183 A MX2020007183 A MX 2020007183A MX 2020007183 A MX2020007183 A MX 2020007183A MX 2020007183 A MX2020007183 A MX 2020007183A
- Authority
- MX
- Mexico
- Prior art keywords
- diseases
- compounds
- formula
- ret9
- methods
- Prior art date
Links
- 229940091171 VEGFR-2 tyrosine kinase inhibitor Drugs 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 230000002062 proliferating effect Effects 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000011594 Autoinflammatory disease Diseases 0.000 abstract 1
- 208000022873 Ocular disease Diseases 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000003102 growth factor Substances 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
En la presente se proporcionan compuestos, composiciones y composiciones farmacéuticas de la Fórmula (1). También se proporcionan en la presente métodos para utilizar los compuestos de la Fórmula (1) para tratar enfermedades proliferativas, enfermedades oculares, enfermedades dermatológicas, enfermedades inflamatorias, enfermedades autoinmunes, enfermedades autoinflamatorias y enfermedades metabólicas. También se proporcionan en la presente métodos para utilizar los compuestos de la Fórmula (1) como agentes terapéuticos, e.g., en el tratamiento y/o prevención de enfermedades asociadas con la actividad del factor de crecimiento o la angiogénesis. En algunas modalidades, la enfermedad que se trata es una enfermedad proliferativa.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762575280P | 2017-10-20 | 2017-10-20 | |
| PCT/US2018/056751 WO2019079747A1 (en) | 2017-10-20 | 2018-10-19 | INHIBITORS OF RET9 AND VEGFR2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020007183A true MX2020007183A (es) | 2021-03-31 |
Family
ID=64277798
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020007183A MX2020007183A (es) | 2017-10-20 | 2018-10-19 | Inhibidores de ret9 y vegfr2. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11401260B2 (es) |
| EP (1) | EP3697775A1 (es) |
| JP (1) | JP2021500346A (es) |
| KR (1) | KR20200074179A (es) |
| CN (1) | CN111465601A (es) |
| AU (1) | AU2018351520A1 (es) |
| BR (1) | BR112020007787A2 (es) |
| CA (1) | CA3079673A1 (es) |
| MX (1) | MX2020007183A (es) |
| WO (1) | WO2019079747A1 (es) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1154774E (pt) * | 1999-02-10 | 2005-10-31 | Astrazeneca Ab | Derivados de quinazolina como inibidores de angiogenese |
| SI1474420T1 (sl) * | 2002-02-01 | 2012-06-29 | Astrazeneca Ab | Spojine kinazolina |
| CN102408411B (zh) * | 2011-09-19 | 2014-10-22 | 北京康辰药业股份有限公司 | 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用 |
| EP2878672A4 (en) * | 2012-07-26 | 2016-02-17 | Nat Cancer Ct | FUSIONSGEN OF CEP55-GEN AND RET-GEN |
| MX368903B (es) * | 2013-02-20 | 2019-10-21 | Kala Pharmaceuticals Inc | Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas. |
| US9458169B2 (en) * | 2013-11-01 | 2016-10-04 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
-
2018
- 2018-10-19 CN CN201880080672.4A patent/CN111465601A/zh active Pending
- 2018-10-19 WO PCT/US2018/056751 patent/WO2019079747A1/en not_active Ceased
- 2018-10-19 CA CA3079673A patent/CA3079673A1/en active Pending
- 2018-10-19 EP EP18801107.6A patent/EP3697775A1/en not_active Withdrawn
- 2018-10-19 JP JP2020521977A patent/JP2021500346A/ja active Pending
- 2018-10-19 KR KR1020207014314A patent/KR20200074179A/ko not_active Abandoned
- 2018-10-19 US US16/757,305 patent/US11401260B2/en active Active
- 2018-10-19 BR BR112020007787-9A patent/BR112020007787A2/pt not_active Application Discontinuation
- 2018-10-19 MX MX2020007183A patent/MX2020007183A/es unknown
- 2018-10-19 AU AU2018351520A patent/AU2018351520A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20210179582A1 (en) | 2021-06-17 |
| CA3079673A1 (en) | 2019-04-25 |
| KR20200074179A (ko) | 2020-06-24 |
| JP2021500346A (ja) | 2021-01-07 |
| BR112020007787A2 (pt) | 2020-10-06 |
| US11401260B2 (en) | 2022-08-02 |
| AU2018351520A1 (en) | 2020-05-07 |
| EP3697775A1 (en) | 2020-08-26 |
| WO2019079747A1 (en) | 2019-04-25 |
| CN111465601A (zh) | 2020-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024010140A (es) | Nuevos metodos. | |
| JOP20200011B1 (ar) | مركبات وتركيبات لمعالجة حالات مرضية مرتبطة بنشاط nlrp | |
| MX2021000148A (es) | Inhibidores eterociclicos de erk1 y erk2 y su uso en el tratamiento del cancer. | |
| MX2023004037A (es) | Compuestos biciclicos como inhibidores alostericos de shp2. | |
| MX2017000612A (es) | Inhibidores de tirosina quinasa del bazo (syk). | |
| EA201990665A1 (ru) | Регуляторы hpk1 на основе производных пиразолопиридина и их применение для лечения рака | |
| SA519401970B1 (ar) | مثبطات حلقية غير متجانسة لناقل مونوكربوكسيلات 4 | |
| MX2018006223A (es) | Moduladores de ror-gamma. | |
| CA2925624C (en) | Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease | |
| MX2017009571A (es) | Inhibidores heterociclicos de itk para el tratamiento de la inflamacion y cancer. | |
| EA201790660A1 (ru) | Ингибитор киназ | |
| EA201591290A3 (ru) | Креноланиб для лечения пролиферативных расстройств, связанных с мутацией flt3 | |
| MX2016003863A (es) | Nuevos derivados de 3-(1h-pirazol-4-il)-1h-pirrolo[2,3-c]piridina como inhibidores de la cinasa inductora de nf-kappab. | |
| PH12017500401A1 (en) | Therapeutic compounds as inhibitors of the orexin-1 receptor | |
| PH12021550872A1 (en) | Therapeutic compounds | |
| SG10201906400SA (en) | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof | |
| WO2016004404A3 (en) | Gls1 inhibitors for treating disease | |
| WO2016090024A3 (en) | Combination therapy for treatment of cancer | |
| EA033237B1 (ru) | Новые производные пиразолопиримидина в качестве ингибиторов nik, фармацевтическая композиция и лекарственное средство, содержащее ее | |
| EA201790563A1 (ru) | Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой | |
| EA201691656A2 (ru) | Терапевтические способы с применением норибогаина и родственных соединений | |
| WO2016004413A3 (en) | Gls1 inhibitors for treating disease | |
| DK3476395T3 (da) | Injicerbar sammensætning omfattende fibroblaster til anvendelse i behandlingen af hjertesygdomme | |
| EP4420722A3 (en) | Modified fibroblast growth factors for the treatment of ocular disorders | |
| EA201792264A1 (ru) | Способы лечения воспалительных заболеваний |